News
Protalix BioTherapeutics, Inc. ( PLX) announced encouraging initial results from a phase I study on its pipeline candidate, PRX-112 an oral glucocerebrosidase (GCD) being evaluated for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback